Nanobody-based canine PD-L1-targeting immune checkpoint inhibitors for cancer therapy in dogs

We are happy to announce our new immune checkpoint inhibitor to fight canine cancers! The inhibitor is composed by two newly discovered anti-cPD-L1 single domain-antibodies (sdAb) binding to two non-overlapping epitopes on the canine PD-L1 molecule. The work was done in collaboration with the groups of Patrick Chames (Aix Marseille University, France) and Johannes vom Berg (University of Zurich, Switzerland).